Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML)

Uday Popat, H. E. Heslop, A. Durett, R. May, R. A. Krance, M. K. Brenner, G. Carrum

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Hemopoietic stem cell transplantation (SCT) with fully ablative conditioning is associated with an age-related increase in treatment-related mortality. It is therefore particularly unsuited to older individuals, who are most at risk of developing acute myeloid leukemia (AML). Reduced-intensity SCT (RISCT) may be of value in this group. We report 17 consecutive patients with high-risk AML whose median age was 58 years and who received stem cells from HLA-matched siblings (n = 5), or alternative donors (n = 12). We used lymphodepleting antibodies as a part of the reduced-intensity conditioning regimen to limit the risk of graft rejection and graft-versus-host disease (GVHD). All patients engrafted. One patient developed severe fatal GVHD, and two patients died of infection. At a median follow-up of 861 days (372 -1957 days), seven patients are alive in remission, which includes two patients treated in relapse and five patients who lacked an MHC identical sibling donor.

Original languageEnglish (US)
Pages (from-to)547-552
Number of pages6
JournalBone Marrow Transplantation
Volume37
Issue number6
DOIs
StatePublished - Mar 2006

Keywords

  • Alemtuzumab
  • AML
  • Elderly
  • Intensity
  • Reduced
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML)'. Together they form a unique fingerprint.

Cite this